ESTHMR إستثمر

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda RMDA

العاشر من رمضان للصناعات الدوائية والمستحضرات تشخيصية-راميدا

Health Care & PharmaceuticalsEgyptian Exchange

5.68 EGP

+0.89%

Close of Thu 12 Nov 2026

Market value
EGP 11.53bn
Highest and lowest close in a year
3.09 – 6.94
Shares traded in the session
6,140,226
Open the full company record in ESTHMR

A chart of every session, the financial statements, the nine checks and filing alerts. Free, with your e-mail and a six-digit code.

About the company

Tenth Of Ramadan Pharmaceutical Industries & Diagnostic (Rameda) is a healthcare company operating in the pharmaceuticals, biotechnology, and life sciences sector, based in 6th of October, Egypt. Established in January 1986 and incorporated on 15 January 1986, it listed on the EGX in December 2019. Major shareholders include LVP PHARMA (30.99%), Saudi Seventh Investment Company (10.92%), and EKUITY B.V. (9.91%). It owns Rameda Pharmaceutical Trading (99.97%), Glow (76.0%), Ramecare (49.0%), and Ramepharma (49.0%).

Its record at the exchange

Across 401 filings from 2019 to 2026, Rameda reported 37 periods of cumulative financial results without reporting a loss in any period. Its lowest full financial year net result was FY 2019 at 82 million EGP, and its highest was FY 2024 at 402 million EGP. Trading was suspended 2 times and resumed 2 times. The company's activity on the exchange peaked in 2022 with 93 filings, and its record includes 5 capital-increase filings and 6 bonus-share filings.

Its latest filings at the exchange

  1. Shareholders' meetingTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) - EGM Invitation
  2. ResultsTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) Reports 9 Months Standalone Results
  3. Release from Tenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) Concerning the Board of Directors & the Executive Managers
  4. ResultsTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) Reports its Financial Results (Consolidated) for the Period from 01/01/2026 to 30/09/2026
  5. Board decisionsTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) - Decisions of the BoD Meeting
  6. Board decisionsTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) - Decisions of the BoD Meeting
  7. Board decisionsTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) - Disclosure Form for the BoD & the Shareholders' Structure
  8. Shareholders' meetingTenth Of Ramadan Pharmaceutical Industries&Diagnostic-Rameda (RMDA.CA) - EGM Minutes (Notarized)

Insider trades in the exchange’s bulletin

As the exchange publishes them in each session’s bulletin: the trader’s capacity, not their name. Each row opens the bulletin itself.

  1. Insider / Board Bought292,000 (0.01% of the company)Bulletin ↗
  2. Connected Group Sold300,000 (0.01% of the company)Bulletin ↗
  3. Insider / Board Sold616,846 (0.03% of the company)Bulletin ↗
  4. Connected Group Sold700,000 (0.03% of the company)Bulletin ↗
  5. Insider / Board Sold2,050,000 (0.10% of the company)Bulletin ↗
  6. Connected Group Sold300,000 (0.01% of the company)Bulletin ↗
  7. Insider / Board Sold35,000 (less than 0.01% of the company)Bulletin ↗
  8. Insider / Board Sold250,000 (0.01% of the company)Bulletin ↗
  9. Insider / Board Sold3,500,000 (0.17% of the company)Bulletin ↗
  10. Insider / Board Sold1,018,726 (0.05% of the company)Bulletin ↗

Other companies in Health Care & Pharmaceuticals

Page updated with the data of 15 Nov 2026.